Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - acamprosate calcium, quantity: 333 mg - tablet, enteric coated - excipient ingredients: methylcellulose; methacrylic acid copolymer; sodium hydroxide; purified talc; crospovidone; magnesium stearate; triethyl citrate; hyprolose - apo-acamprosate is indicated as therapy to maintain abstinence in alcohol dependent patients. it should be combined with counselling

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium delayed-release tablets are contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium delayed-release tablets are contraindicated in patients with severe renal

United States - English - NLM (National Library of Medicine)

avkare - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤ 30 ml/min) [see dosage and administration (2.1), warn

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablet treatment. the efficacy of acamprosate calcium in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium delayed-release tablets are contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium delayed-release tablets are contraindicated in patients with severe renal impairment (creatinine clearance of ≤ 30 ml/min)

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤30 ml/mi

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤ 30 ml/min) [see dosage and administration (2.1), warnings an

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤30 ml/min) [s

United States - English - NLM (National Library of Medicine)

american health packaging - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg - acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. the efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤30 ml/min)

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - acamprosate calcium, quantity: 333 mg - tablet, enteric coated - excipient ingredients: magnesium silicate dihydrate; purified talc; propylene glycol; sodium starch glycollate; colloidal anhydrous silica; crospovidone; magnesium stearate; microcrystalline cellulose; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate - acamprosate viatris is indicated as therapy to maintain abstinence in alcohol dependent patients. it should be combined with counselling.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - acamprosate calcium (unii: 59375n1d0u) (acamprosate - unii:n4k14ygm3j) - acamprosate calcium 333 mg